Robyn K. Crow
Research Subjects
Robyn K. Crow has a total of 12 co-authors. Here are the top co-authors by number of shared publications:
- Alycia Ketter
Wright State University
1 shared publication - Anita Thyagarajan
Department of Pharmacology and Toxicology, Boonshoft School of Medicine Wright State University Dayton Ohio USA
1 shared publication - Catherine Mary Turner Sherwin
Internal Medicine, UWA Medical School, The University of Western Australia
1 shared publication - Craig A. Rohan
Wright State University Boonshoft School of Medicine, Beavercreek, USA
1 shared publication - Danielle A. Corbin
Departments Pharmacology & Toxicology
1 shared publication - Garrett W. Fisher
Wright State University
1 shared publication
Latest Publications
- Open Access
Possible involvement of keratinocyte-derived microvesicle particles in human photosensitivity disorders
Background: Previous murine studies have implicated acid sphingomyelinase-(aSMase) generated subcellular microvesicle particles (MVP) in photosensitivity. Objective: The current double-blinded placebo-controlled studies examined if a single localized ultraviolet B radiation (UVB) treatment generated more MVP in human subjects with self-identified photosensitivity versus normal controls. A topical 4% formulation of the aSMase inhibitor imipramine applied immediately after UVB blocked the MVP release and erythema responses. Erythema responses at 24 and 72 h in response to multiple UVB fluences and minimal erythema doses (MED) at 24 h and effects of imipramine were also tested. Results: Small cohorts of 10 adult self-identified photosensitive subjects and 10 controls were enrolled in these pilot studies which revealed increased levels of skin MVP in UVB-treated photosensitive subjects over controls which correlated with MED values. Moreover, post-UVB application of imipramine blunted UVB-induced MVP responses as well as tended to diminish erythema levels at 4 h but not at 24- or 72 h in photosensitive patients. Conclusion: Though limited by low numbers of self-identified subjects, these pilot studies provide some support for the hypothesis that MVP could be involved in multiple types of human photosensitivity responses and suggest aSMase inhibition as a potential therapeutic strategy.
Open AccessPossible involvement of keratinocyte-derived microvesicle particles in human photosensitivity disorders
Background: Previous murine studies have implicated acid sphingomyelinase-(aSMase) generated subcellular microvesicle particles (MVP) in photosensitivity. Objective: The current double-blinded placebo-controlled studies examined if a single localized ultraviolet B radiation (UVB) treatment generated more MVP in human subjects with self-identified photosensitivity versus normal controls. A topical 4% formulation of the aSMase inhibitor imipramine applied immediately after UVB blocked the MVP release and erythema responses. Erythema responses at 24 and 72 h in response to multiple UVB fluences and minimal erythema doses (MED) at 24 h and effects of imipramine were also tested. Results: Small cohorts of 10 adult self-identified photosensitive subjects and 10 controls were enrolled in these pilot studies which revealed increased levels of skin MVP in UVB-treated photosensitive subjects over controls which correlated with MED values. Moreover, post-UVB application of imipramine blunted UVB-induced MVP responses as well as tended to diminish erythema levels at 4 h but not at 24- or 72 h in photosensitive patients. Conclusion: Though limited by low numbers of self-identified subjects, these pilot studies provide some support for the hypothesis that MVP could be involved in multiple types of human photosensitivity responses and suggest aSMase inhibition as a potential therapeutic strategy.